Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Otofarma SpA's gross profit for the
six
months ended in Dec. 2024 was €13.46 Mil. Otofarma SpA's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was €13.46 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Otofarma SpA's gross profit for the
six
months ended in Dec. 2024 was €13.46 Mil. Otofarma SpA's Revenue for the
six
months ended in Dec. 2024 was €15.20 Mil. Therefore, Otofarma SpA's Gross Margin % for the quarter that ended in Dec. 2024 was 88.55%.
Otofarma SpA had a gross margin of 88.55% for the quarter that ended in Dec. 2024 => Durable competitive advantage
During the past 2 years, the highestGross Margin % of Otofarma SpA was 88.55%. The lowest was 84.12%. And the median was 86.34%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Otofarma SpA had a gross margin of 88.55% for the quarter that ended in Dec. 2024 => Durable competitive advantage
Otofarma SpA Gross Profit Related Terms
Otofarma SpA Gross Profit Historical Data
* Premium members only.
The historical data trend for Otofarma SpA's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Otofarma SpA Gross Profit Chart
Otofarma SpA Annual Data
Trend
Dec23
Dec24
Gross Profit
10.14
13.46
Otofarma SpA Semi-Annual Data
Dec23
Dec24
Gross Profit
10.14
13.46
MIL:OTO vs ABT, SYK, MDT: Gross Profit Comparison
For the Medical Devices subindustry, Otofarma SpA's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Otofarma SpA Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Otofarma SpA's Gross Profit distribution charts can be found below:
* The bar in red indicates where Otofarma SpA's Gross Profit falls into.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 was €13.46 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Otofarma SpA (MIL:OTO) has a Gross Profit of €13.46 Mil as of Dec. 2024. Gross Profit equals net sales less total cost of goods sold. View historical data on Otofarma SpA and its competitors.
Is Otofarma SpA's Gross Profit too high?
Otofarma SpA's current Gross Profit is €13.46 Mil. Overall, Otofarma SpA has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Otofarma SpA's Gross Profit compare to ABT and SYK?
Otofarma SpA's Gross Profit of €13.46 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Otofarma SpA and its competitors. Otofarma SpA's current Gross Profit is €13.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Otofarma SpA stock overvalued right now?
Otofarma SpA (MIL:OTO) has a current Gross Profit of €13.46 Mil. The current Gross Profit is €13.46 Mil. Otofarma SpA's overall GF Score™ is 16/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Otofarma SpA (MIL:OTO), the current Gross Profit is €13.46 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Otofarma SpA is engaged in the construction and production of hearing aids, is constantly growing in the audiological field to provide adequate responses to every type of hearing aid need to its customers who require the possible personalized application of custom-made hearing aids. It provides otoacoustic medical devices and TELEMEDICINE services exclusively in affiliated pharmacies, possessing a portfolio of Instrumental IT patents.
16GF Score
Get the complete analysis for MIL:OTO
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:OTO has been successfully added to your 
